After Krystal Biotech announced the official opening of its new cGMP facility located in Pittsburgh, H.C. Wainwright analyst Joseph Pantginis said the plant opening represents an “important box checked” and demonstrates that the company is favorably positioned to address the current and future manufacturing needs of its assets. The analyst, who said KB103 is “moving quickly towards pivotal,” keeps a Buy rating and $32 price target on Krystal Biotech shares
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.